Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.74 |
| ▸ | TDO2 | P48775 | 20/20 | 0.74 |
| ▸ | IDO2 | Q6ZQW0 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7227619 | 0.97 | IDO1 (0.75) | IDO1TDO2IDO2 | |
| SCHEMBL98113 | 0.86 | IDO1 (0.64) | IDO1TDO2IDO2 | |
| SCHEMBL14041261 | 0.86 | IDO1 (0.83) | IDO1TDO2IDO2 | |
| SCHEMBL14041192 | 0.86 | IDO1 (1.00) | IDO1TDO2IDO2 | |
| SCHEMBL127629 | 0.75 | IDO1 (0.46) | IDO1TDO2IDO2 | |
| SCHEMBL27280965 | 0.75 | IDO1 (0.46) | IDO1TDO2IDO2 | |
| Methane SCHEMBL29089947 | 0.73 | IDO1 (0.44) | IDO1TDO2IDO2 | |
| Water SCHEMBL11878861 | 0.73 | IDO1 (0.44) | IDO1TDO2IDO2 | |
| Ammonia Solution, Strong SCHEMBL7282272 | 0.73 | IDO1 (0.44) | IDO1TDO2IDO2 | |
| SCHEMBL29233222 | 0.72 | IDO1 (0.45) | IDO1TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | claimed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| US-20090136461-A1 | Neuronal differentiation method of adult stem cells using small molecules | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-05-28 | — | — | US | claimed |
| US-6048707-A | ANALYZING STRUCTURAL RELATIONSHIP BETWEEN MONOSACCHARIDES OF CARBOHYDRATE; DERIVATIZING CARBOHYDRATE, CONVERTING TO MONOSACCHARIDES, FORMING LABELED MONOSACCHARIDES, SEPARATING MONOSACCHARIDES BY ELECTROPHORESIS, DETECTING MONOSACCARIDES | GLYKO, INC. (US) | 2000-04-11 | — | — | US | claimed |
| US-20240218170-A1 | POLYIMIDE RESIN COMPOSITION, POLYIMIDE-BASED ADHESIVE COMPOSITION, POLYIMIDE ADHESIVE FILM, AND FLEXIBLE METAL CLAD LAMINATE FILM | NEXFLEX CO., LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| EP-3011961-A1 | 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation | Biokine Therapeutics LTD. (IL) | 2016-04-27 | — | — | EP | disclosed |
| EP-2942059-A1 | 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Biokine Therapeutics LTD. (IL) | 2015-11-11 | — | — | EP | disclosed |
| WO-1992002495-A1 | CYCLOPENTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT BERLIN/BERGKAMEN (DE) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002494-A1 | CYCLOPENTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT BERLIN/BERGKAMEN (DE) | 1992-02-20 | — | — | WO | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
| WO-1991014675-A1 | BICYCLO[3.3.)]OCTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-10-03 | — | — | WO | disclosed |
| EP-0386487-A1 | Novel N-(substituted aryl)-N'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents | WARNER-LAMBERT COMPANY (US) | 1990-09-12 | — | — | EP | disclosed |
| US-4923896-A | N-(substituted aryl)-N'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents | WARNER-LAMBERT COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| US-4385177-A | Cephalosporins having a carbamoylalkoxyiminoarylacetamido group at 7-position | GLAXO LABORATORIES, LTD. (GB) | 1983-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885TDO2 4/4885IDO2 2/4885 |
| US-20090136461-A1 | Neuronal differentiation method of adult stem cells using small molecules | DCX, NES, GAP43 | IDO1 4046/4885TDO2 4800/4885IDO2 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.